Current treatment of non‐alcoholic fatty liver disease
- 27 January 2009
- journal article
- review article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 11 (3) , 188-195
Abstract
Non‐alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in Western World and frequently associated with insulin resistance and overweight and occurs often with type 2 diabetes. Interestingly, NAFLD is not only regarded as a hepatic component of the metabolic syndrome but also as an independent risk factor and a marker for increase in cardiovascular disease (CVD). Significantly, NAFLD is associated with an increased risk of all‐cause mortality and predicts future CVD events independent of age, sex, LDL‐cholesterol and features of metabolic syndrome. Although there was initial concern about drug toxicity with NAFLD, increasing evidence suggests that commonly used drugs such as metformin and statins do not cause harm and the thiazolidinediones (TZDs) may even confer a therapeutic benefit in NAFLD. Interestingly, medical and surgical treatments of obesity show potential benefit in treating NAFLD. In this review, we have focused on the safety and therapeutic impact of TZDs, statins, metformins and obesity medications in NAFLD. The potential benefit of bariatric surgery and the role of weight loss per se in treating NAFLD are also discussed.Keywords
This publication has 53 references indexed in Scilit:
- Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)Drug Discovery Today, 2007
- Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetesJournal of Diabetes and its Complications, 2007
- The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver DiseaseDigestive Diseases and Sciences, 2007
- The Effect of a Low-Carbohydrate, Ketogenic Diet on Nonalcoholic Fatty Liver Disease: A Pilot StudyDigestive Diseases and Sciences, 2007
- Effect of vitamin E on aminotransferase levels and insulin resistance in children with non‐alcoholic fatty liver diseaseAlimentary Pharmacology & Therapeutics, 2006
- An Assessment of Statin Safety by HepatologistsThe American Journal of Cardiology, 2006
- Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosisSurgery, 2004
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- Pioglitazone and Metformin Reverse Insulin Resistance Induced by Tumor Necrosis Factor-Alpha in Liver CellsHormone and Metabolic Research, 1997